US OptionsDetailed Quotes

CSTL250117C40000

Watchlist

0.05
0.000.00%

15min DelayClose Dec 27 16:00 ET

0.00High0.00Low

Castle Biosciences Stock Discussion

Stock_Drift

Oct 20 04:18

$Castle Biosciences (CSTL.US)$

Teddy123

Sep 29 21:15

New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients w

$Castle Biosciences (CSTL.US)$
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma | CSTL Stock News

Iwill TradeScared

Sep 3 11:38

$Castle Biosciences (CSTL.US)$

Iwill TradeScared

Aug 30 11:51

$Castle Biosciences (CSTL.US)$

Trytosaveabit

May 29 15:33

Nice!

$Castle Biosciences (CSTL.US)$ New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis 1 MINUTE AGO, 4:30 PM EDT VIA BUSINESSWIRE

Moomoo AI

Mar 17 08:44

Despite impressive revenue growth, the high P/S ratio and average growth expectations make the share price seem overvalued. Predicted future revenues may not support this positive sentiment, risking shareholders' investments and potential investors paying a premium.

More Unpleasant Surprises Could Be In Store For Castle Biosciences, Inc.'s (NASDAQ:CSTL) Shares After Tumbling 25%

Moomoo AI

Mar 3 07:37

Castle Biosciences' progress over the last year is impressive, and it is well-positioned to raise more cash for growth with minimal dilution or borrowing. Its cash burn situation is not risky due to revenue growth and cash burn reduction.

Here's Why We're Not At All Concerned With Castle Biosciences' (NASDAQ:CSTL) Cash Burn Situation

Moomoo AI

Jan 27 08:08

Investors are confident in Castle Biosciences' future growth despite its high P/S ratio. The strong future revenue growth justifies the high P/S ratio, making a significant share price drop unlikely.

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Moomoo AI

Jan 7 19:18

Derek Maetzold, president and CEO of Castle Biosciences, sees the robust revenue and test volume growth as a testament to their successful execution of growth initiatives. He is optimistic about the sustainability of this growth and momentum into 2024.

Press Release: Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

Trytosaveabit

Oct 18, 2023 15:36

On watch

$Castle Biosciences (CSTL.US)$ Keeping a close eye to see what comes out of this? (. New Data Highlights Clinical Utility and Performance of Castle Biosciences' Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference
Businesswire· 4 mins ago

Weight-loss drugmakers report strong earnings: Boon or bane?

No comment yet